MultiStem

I schemic stroke is caused by a blockage of blood flow to the brain. A leading cause of death and disability globally, each year… (More)

: MultiStem cells are clinical-grade multipotent adult bone marrow-derived progenitor cells (MAPCs), with extensive replication… (More)

We conducted a multicenter, phase 1 dose escalation study evaluating the safety of the allogeneic multipotent adult progenitor… (More)

BACKGROUND There is growing interest in neurorestorative and reparative therapies after acute stroke. MultiStem is an allogeneic… (More)

RATIONALE MultiStem is an allogeneic bone marrow-derived adherent adult stem cell product that has shown efficacy in preclinical… (More)

Mucopolysaccharidosis type I (MPS-I; Hurler syndrome) is an inborn error of metabolism caused by lack of the functional lysosomal… (More)

The last decade has seen much progress in adjunctive cell therapy for immune disorders. Both corporate and institutional Phase… (More)

Athersys (Nasdaq: ATHX) is a biopharmaceutical company engaged in the discovery and development of novel therapies designed to… (More)

The therapeutic benefits of adult adherent stem cells are currently being investigated in clinical trials for a variety of… (More)

BACKGROUND Successful clinical development of novel cellular therapeutics requires the evaluation of clinical acute toxicity… (More)